Published in Cancer Res on March 01, 2002
Sphingosine 1-phosphate and cancer. Nat Rev Cancer (2010) 3.95
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J (2011) 1.59
The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood (2006) 1.41
FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem (2011) 1.37
Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J Biol Chem (2009) 1.32
Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol (2012) 1.31
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest (2003) 1.16
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett (2008) 1.07
S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood (2012) 1.02
Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. Cancer Ther (2007) 1.02
FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One (2012) 1.01
PP2A-Mediated Anticancer Therapy. Gastroenterol Res Pract (2013) 1.01
Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res (2014) 1.01
Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res (2011) 0.99
FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem (2007) 0.97
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle (2012) 0.96
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis (2015) 0.96
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol (2006) 0.95
STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. Neoplasia (2013) 0.93
Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages. Eur J Immunol (2011) 0.92
A review of ceramide analogs as potential anticancer agents. Future Med Chem (2013) 0.92
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget (2015) 0.92
The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. Lymphat Res Biol (2012) 0.92
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer (2014) 0.89
Roles of sphingosine 1-phosphate on tumorigenesis. World J Biol Chem (2011) 0.89
Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond. Anticancer Agents Med Chem (2011) 0.88
PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer. Genes Cancer (2012) 0.87
Inhibition of Hypoxia-Induced Cell Motility by p16 in MDA-MB-231 Breast Cancer Cells. J Cancer (2010) 0.87
Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells. J Virol (2010) 0.86
Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Mol Sci (2014) 0.84
The transmembrane domains of L-selectin and CD44 regulate receptor cell surface positioning and leukocyte adhesion under flow. J Biol Chem (2010) 0.84
Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets (2010) 0.84
Inhibition of Breast Tumor Cell Growth by Ectopic Expression of p16/INK4A Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition. J Cancer (2012) 0.83
TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. Bonekey Rep (2015) 0.82
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer (2013) 0.82
The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget (2016) 0.82
Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast. PLoS One (2013) 0.81
Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like Protein. Mol Biol Int (2012) 0.81
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya). ACS Med Chem Lett (2013) 0.80
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics (Sao Paulo) (2013) 0.80
Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis. Int J Mol Sci (2010) 0.79
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J Cell Mol Med (2015) 0.78
Interstitial Fluid Sphingosine-1-Phosphate in Murine Mammary Gland and Cancer and Human Breast Tissue and Cancer Determined by Novel Methods. J Mammary Gland Biol Neoplasia (2016) 0.77
Attacking the supply wagons to starve cancer cells to death. FEBS Lett (2016) 0.77
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo. ACS Chem Biol (2015) 0.77
Effects of Hypoxia, Surrounding Fibroblasts, and p16 Expression on Breast Cancer Cell Migration and Invasion. J Cancer (2015) 0.76
Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways. J Clin Invest (2016) 0.76
FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity. Pharmacol Res Perspect (2015) 0.76
Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget (2016) 0.75
Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Sci Rep (2016) 0.75
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med (2017) 0.75
Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1α Screening and Validation System. J Cancer (2016) 0.75
Gene expression profile in the regenerating rat liver after partial hepatectomy. J Hepatol (2003) 2.43
Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst (2005) 2.23
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol (2012) 2.13
Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant (2004) 1.93
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther (2003) 1.73
Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant (2008) 1.55
Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol (2008) 1.55
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci (2007) 1.50
Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl (2012) 1.49
Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years. Int J Urol (2009) 1.48
Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis. Cell Transplant (2012) 1.47
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Participation of autophagy in renal ischemia/reperfusion injury. Biochem Biophys Res Commun (2008) 1.46
Juxtaglomerular cell tumor that was preoperatively diagnosed using selective renal venous sampling. Intern Med (2013) 1.44
A single nucleotide polymorphism within the novel sex-linked testis-specific retrotransposed PGAM4 gene influences human male fertility. PLoS One (2012) 1.44
The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest (2008) 1.44
Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia. Urology (2011) 1.43
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther (2010) 1.43
Adipose tissue-derived stem cells suppress acute cellular rejection by TSG-6 and CD44 interaction in rat kidney transplantation. Transplantation (2014) 1.43
Microvessel area of immature vessels is a prognostic factor in renal cell carcinoma. Int J Urol (2013) 1.42
White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol (2013) 1.41
Circulating Fibroblast Growth Factor 23 Has a U-Shaped Association With Atrial Fibrillation Prevalence. Circ J (2015) 1.41
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology (2005) 1.40
Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy. Int J Urol (2015) 1.40
Clinical significance of calcification in ascending aorta as a marker for the requirement of coronary revascularization. J Atheroscler Thromb (2009) 1.39
The relationship of fibroblast growth factors 21 and 23 and α-Klotho with platelet activity measured by platelet volume indices. Clin Chem Lab Med (2015) 1.39
Bone marrow-derived cells contribute to regeneration of injured prostate epithelium and stroma. Prostate (2015) 1.38
Vascular Behçet's disease with coronary artery aneurysm. Intern Med (2006) 1.32
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28
Renal cell carcinoma in dialysis patients: a single center experience. Int J Urol (2006) 1.26
Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys (2010) 1.22
Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol (2006) 1.21
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer (2007) 1.21
Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res (2004) 1.21
Redox factor-1/APE suppresses oxidative stress by inhibiting the rac1 GTPase. FASEB J (2002) 1.19
Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol (2003) 1.18
Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis (2004) 1.18
Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol (2008) 1.15
Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res (2005) 1.14
Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol (2007) 1.14
The endoscopic surgical skill qualification system in urological laparoscopy: a novel system in Japan. J Urol (2006) 1.13
[A case report of prostatic stromal tumor of uncertain malignant potential (STUMP)]. Hinyokika Kiyo (2008) 1.11
Transplantation of spermatogonial stem cells isolated from leukemic mice restores fertility without inducing leukemia. J Clin Invest (2005) 1.11
Risk factors for malignancy in Japanese renal transplant recipients. Cancer (2007) 1.10
Mouse germ cell-less as an essential component for nuclear integrity. Mol Cell Biol (2003) 1.09
Inflammation and prostate carcinogenesis. Int J Urol (2012) 1.07
Single-nucleotide polymorphisms of the PRDM9 (MEISETZ) gene in patients with nonobstructive azoospermia. J Androl (2009) 1.07
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis (2003) 1.07
[A case report of retrocaval ureter associated with right ureteral tumors]. Hinyokika Kiyo (2011) 1.07
Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res (2003) 1.06
Laparoscopic nephroureterectomy for upper tract transitional cell carcinoma: comparison of laparoscopic and open surgery. Eur Urol (2005) 1.06
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol (2011) 1.06
COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res (2007) 1.06
AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail (2008) 1.06
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res (2003) 1.05
Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun (2012) 1.05
Single nucleotide polymorphisms in the protamine-1 and -2 genes of fertile and infertile human male populations. Mol Hum Reprod (2003) 1.04
High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol (2006) 1.04
Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol (2008) 1.04
Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab (2006) 1.04